HAE

Business Context and Reporting Period

Company: Haemonetics Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: April 1, 2000
Business Overview: Haemonetics designs, manufactures, and markets automated systems for the collection, processing, and surgical salvage of blood. The company operates as a single segment focused on blood component therapy, surgical blood salvage, plasma collection, and automated red cell collection. Key markets include hospitals, blood banks, and commercial plasma centers globally.

Key Financial Metrics

Revenue Composition: Disposable products accounted for approximately 90% of net revenues. Equipment sales represented 5.5% of revenues, down from 7.4% in the prior year.

Material Changes vs. Prior Period

• Revenue Decline: Reported net revenues decreased 1.5% primarily due to unfavorable foreign exchange rates (3.9% less favorable than FY1999) and a 27.5% drop in equipment sales. On a constant currency basis, revenues increased 1.7%.
• Unusual Charge: Operating income was significantly impacted by a $9.5 million unusual charge in Q4 2000 related to a write-down of sales-type lease investments in China due to intellectual property issues and restrictive local regulations.
• Cost Savings: The "Customer Oriented Redesign for Excellence" (CORE) program generated $3.6 million in savings in FY2000, contributing to gross profit improvements on a constant currency basis.
• Strategic Investment: The company invested $15.2 million for a 19.8% stake in Transfusion Technologies Corporation to distribute the OrthoPAT autotransfusion system in Europe and Asia.
• Divestiture Completion: The company completed the divestiture of its Blood Bank Management Services (BBMS) division, resulting in a $144,000 gain from the reversal of excess reserves.

Guidance, Outlook, and Risks

Outlook and Initiatives:

• Product Pipeline: The company expects FDA clearance for a new red cell collection system with integrated leukoreduction by the end of calendar 2000. A pathogen inactivation system for red blood cells (in collaboration with VITEX) is projected for launch by fiscal year 2004.
• Market Growth: Management projects sales from the emerging red cell apheresis market to reach $30 million by FY2003 and $120 million by FY2005.
• Cost Targets: The CORE program targets an additional $3 million in savings for each of fiscal years 2001 and 2002.
• Tax Rate: An effective tax rate of 29% is anticipated for fiscal year 2001.

Risks and Contingencies:

• China Operations: Continued uncertainty regarding intellectual property protection and "knock-off" disposables in China poses a risk to future investments in that region.
• Regulatory: The company faces ongoing regulatory hurdles, including FDA approvals for new devices and solutions. Delays in approval could impact revenue projections.
• Foreign Exchange: Over two-thirds of revenues are generated outside the U.S. Fluctuations in the Euro and Japanese Yen significantly impact reported results.
• Customer Concentration: One unaffiliated Japanese customer accounted for 29.3% of total sales in FY2000.

Investor Verification Checklist

• China Asset Valuation: Verify the remaining book value of the China sales-type leases and the assumptions used for the $9.5 million write-down.
• Constant Currency Performance: Confirm the 4.6% growth in disposable sales on a constant currency basis to assess underlying business health independent of FX volatility.
• Transfusion Technologies Investment: Review the terms of the 19.8% stake and the exclusivity agreement for the OrthoPAT system to evaluate potential ROI.
• Regulatory Milestones: Monitor the status of the 510(k) application for the leukoreduction filter and the NDA for the red cell washing system.
• Debt Structure: Note the shift in debt maturity, with $32.9 million due within the next 12 months, and assess liquidity coverage.